



PIONEER

PIONEER's systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer. Is there a need for a core outcome set?

Authors: Katharina Beyer¹; Steven MacLennan²; Michael Lardas³; Lisa Moris⁴; Eleni Vradi⁵; Muhammad Imran Omar²; Sara Jane MacLennan²; Alberto Briganti⁶; Mieke Van Hemelrijck¹

¹King's College London, Faculty of Life Sciences and Medicine, Translational and Oncology Research (TOUR), London, UK; ²Academic Urology Unit, Health Services Research Unit, University of Aberdeen, Aberdeen, UK; ³Department of Reconstructive Urology and Surgical Andrology, Metropolitan General Hospital, Athens, Greece; ⁴Department of Urology, University Hospitals Leuven, Leuven, Belgium; ⁵Department of Epidemiology, Bayer AG, Berlin, Germany; ⁶Department of Urology, University Vita e Salute-San Raffaele, Milan, Italy

Background


Harmonising assessment of men with prostate cancer (PCa) is key for both clinical research and practice.

- Core outcome sets (COS) are an agreed minimum set of outcomes.
- As part of the PIONEER Consortium, we aim to develop COS to cover the various stages and of treatments for prostate cancer (Figure 1).

Introduction

This systematic review aims to determine if there is a need for a non-metastatic castration resistant prostate cancer (nmCRPC) core outcome set (COS).

Figure 1: Research overview to develop PIONEER COS



Methods


We systematically reviewed RCTs of any intervention for men with nmCRPC published between 1.01.2014 and 21.12.2018.

- The search criteria were extended to include metastatic castration resistant prostate cancer (mCRPC), hormone resistant prostate cancer (HRPC), metastatic prostate cancer (mPC)

Results and Discussion


- Literature searches identified 1,262 citations for men with nmCRPC, mCRPC, HRPC, mPC from which five RCTs met the inclusion criteria.

Figure 2: PRISMA diagram



- reports outcomes for nmCRPC, which differ from the already identified outcomes in the PIONEER metastatic outcome set.

Figure 3: Outcomes identified in nmCRPC systematic review (not captured in mPCa COS)



Conclusion

- Very few new outcomes were identified for nmCRPC as compared with the metastatic setting.
- Therefore, PIONEER currently does not recommend a specific COS for nmCRPC
- If in future further treatment options warrant new RCTs and different outcome measurements, this recommendation may change.